气相色谱电子捕获检测法测定人尿中氟硝西泮的代谢物7-氨基氟硝西泮

采用气相色谱电子捕获检测法测定人尿中氟硝西泮的代谢物 7 氨基氟硝西泮。测定时尿中加入内标 7 氨基硝西泮 ,用β 葡萄糖醛酸苷酶水解及碱性液液萃取 ,再用七氟丁酸酐衍生化。尿中 7 氨基氟硝西泮提取率为 96.8% ;回收率为 98.6± 3 .4% (平均值±SD) ;检出限为 1 .2 μg L ,对口服治疗量氟硝西泮的人尿进行检测 ,可检出服药后 60h尿中的 7 氨基氟硝西泮。     

中空纤维膜液相微萃取-气相色谱/三重四级杆质谱法检测尿液和血液样品中8种毒品

建立了生物样品尿液和血液中8种毒品的中空纤维膜液相微萃取-气相色谱/三重四级杆质谱检测方法。对影响萃取富集效率的因素通过正交试验进行优化,确定最佳条件如下:选择甲苯作为萃取剂,在样品溶液pH=13.0的条件下用5cm长的中空纤维膜进行萃取,萃取温度为30℃,搅拌速度为600r·min~(-1)。萃取后抽取有机溶剂供气相色谱/三重四级杆质谱分析检测。结果表明,各分析物在0.0003~10μg·mL~(-1)范围具有良好的线性关系,线性相关系数R在0.9985~0.9995之间;检出限(S/N=3)为0.05~0.5ng·mL~(-1);样品加标回收率在79.3%~98.6%之间,相对标准偏差(RSD)4.5%(n=5)。该方法具有净化能力好、操作简单、灵敏度高和重现性好等优点,能用于生物样品中多种毒品的高灵敏度分析检测。     

萃取-原子吸收分光光度法测定卤水中的铷和铯

用取代酚尤其是4-仲丁基-2-(α-甲苄基)酚(BAMBP)萃取铷和铯已引起很大的注意。萃取铷和铯最适宜的NaOH和BAMBP的浓度是1.0M。锂、钠离子没有明显萃取。加入试剂之前,如果加入适当量的酒石酸钠用作掩蔽剂,可防止镁和铁离子的沉淀。本法成功地应用于卤水中定量测定铷和铯,其检测限比一般方法低,相对误差±6％。方法快速、简便、灵敏。我们原先采用大粒度磷钼酸铵富集后,用碱溶解再以BAMBP萃取进行测定。以后     

三甲基硅烷衍生化-气相/质谱联用法分析尿中7-氨基硝西泮

 建立了分析尿中硝西泮主要代谢物 7 氨基硝西泮 (7 ANIZ)的三甲基硅烷衍生化 气相 /质谱联用方法。尿样经乙醚 乙酸乙酯 (体积比为 99∶1 )萃取后 ,用N ,O 双 (三甲基硅 )三氟乙酰胺进行衍生化 ,检测衍生物的总离子流。根据 7 ANIZ衍生物质谱中主要特征离子的相对丰度及其质量的保留时间进行定性分析 ;用 7 氨基氯硝西泮做内标 ,根据衍生物基峰离子的质量进行定量分析。本方法中 7 ANIZ的萃取率为 82 8% ,线性范围为 1 0 μg/L～ 50 0 μg/L,检出限为 1 2 μg/L,定量限为 3 5μg/L。     

还原萃取-库仑滴定法测定微克量砷

拟定了在小体积容量瓶中,在KBr存在下,以Fe(Ⅱ)作还原剂,用甲苯作萃取剂,从7.5mol/LH_2SO_4介质中一次性还原萃取砷,再用0.2mol/L KI(pH=9碳酸盐缓冲液)先质溶液一次性反萃取,然后用电生Ⅰ_2作库仑滴定剂,电位法检测终点测定砷的方法。检测限为0.5μg/25mL,测定1～20μgAs(Ⅲ),回收率为100±10％,应用于矿石分析,结果与经典比色法相符。本法还可应用于钢铁分析。     

固相萃取-超高效液相色谱/串联质谱同时检测饮料中13种禁限用食品添加剂

建立了固相萃取-超高效液相色谱/电喷雾电离串联质谱(SPE-UPLC-MS/MS)同时测定饮料中13种禁限用食品添加剂(甜味剂、防腐剂和色素类物质)的分析方法。样品经过OASIS HLB固相萃取小柱萃取净化后,以0.2mL/min的流速,在WatersBEH C18(50×2.1mm,1.7μm)色谱柱上进行快速分离,流动相为10mmol/L乙酸铵(含0.1%乙酸)和甲醇。根据检测物质的性质,利用不同电离模式(ESI-和ESI+),采用多反应监测模式(MRM)进行测定,在2～500μg/L的范围内,各物质线性相关系数均大于0.990,13种检测物质的检出限为0.20～6.79μg/L;利用Waters HLB固相萃取小柱对目标物质进行萃取,对固相萃取条件进行优化后,10、50、100μg/L三个添加水平下平均回收率为85.6%～110.4%,相对标准偏差(RSD)均小于10%(n=5)。所建立的方法简便,灵敏度高,可以满足对饮料中多种不同食品添加剂的同时测定。     

固相萃取-气相色谱-质谱法分析尿液中邻苯二甲酸单酯和双酯

建立了固相萃取-气相色谱-质谱测定尿液中邻苯二甲酸单酯和双酯的分析方法。尿液经 β-葡萄糖苷酸酶酶解后进行固相萃取净化,用乙腈、乙酸乙酯和乙醚-正己烷(1: 19, v/v)分别洗脱,合并洗脱液,氮气吹干后,用N,O-双三甲基硅基三氟乙酰胺(BSTFA)对邻苯二甲酸单酯进行硅烷化处理,使用气相色谱-质谱法检测。邻苯二甲酸单酯和双酯的线性范围为5~1000 μ g/L,检出限为0.3~1.1 μ g/L,回收率为77.9%~97.7%,相对标准偏差为3.7%~10.9%。应用该方法对50份尿液进行检测,检出邻苯二甲酸二(2-乙基己基)酯(DEHP)等7种邻苯二甲酸单酯和双酯类物质,平均质量浓度为6.0~142.7 μ g/L。该方法准确、可靠、灵敏度高,适用于尿液中邻苯二甲酸单酯和双酯的同时测定。     

TBP-二甲苯萃取分离荧光法测定人体尿中微量铀

研究了磷酸三丁酯 (TBP) 二甲苯直接从人体尿样中采用萃取有机相烧制荧光球珠萃取分离铀 ,荧光法测定人体尿样中的微量铀。结果表明 ,方法的回收率达 98% ,相对标准偏差≤± 12 % ,最低检测浓度为 1× 10 - 7g·L- 1(5× 10 - 10 g/球 )。     

环境水中甲基对硫磷、对硫磷和辛硫磷农药残留的SPE-HPLC分析

采用离线固相萃取 (SPE)富集 -高效液相色谱(HPLC)分离和紫外分光光度法检测 ,对环境水中甲基对硫磷、对硫磷和辛硫磷3种有机磷农药进行分析;固相萃取用C18 萃取柱 ,用甲醇洗脱 ,高效液相色谱分离以Shim_PackCLCODS柱(150mm×4.6mmid,5μm)为分离柱 ,流动相为甲醇 -水(体积比70∶30) ,紫外检测波长为280nm;该法稳定可靠 ,回收率高     

分散固相萃取-气相色谱-质谱法测定含油脂食品中17种邻苯二甲酸酯

建立了含油脂食品中17种邻苯二甲酸酯的分散固相萃取-气相色谱-质谱法检测方法。奶茶样品经乙腈-甲基叔丁基醚(9∶1,V/V)提取后,提取液用MAS-PAEC分散固相萃取管进行净化。调味包样品经乙腈(正己烷饱和)-甲基叔丁基醚(19∶1,V/V)提取2次后,提取液用CNW分散固相萃取管进行净化。采用基质匹配标准外标法进行定量分析。结果表明,奶茶中17种邻苯二甲酸酯的加标回收率为82.2%～125.4%;相对标准偏差小于16.5%;方法检出限为100～200μg/L。调味包中17种邻苯二甲酸酯的加标回收率为70.9%～115.5%;相对标准偏差小于9.8%;方法检出限为400～800μg/L。本方法快速、精确、简易、廉价、稳定,可应用于含油脂食品中17种邻苯二甲酸酯的实际检测分析。     

Two- and three-way chemometrics methods applied for spectrophotometric determination of lorazepam in pharmaceutical formulations and biological fluids

In this work, direct determination of lorazepam, an anxiolytic and sedative agent, in pharmaceutical formulations and biological fluids (urine and human plasma) was accomplished based on ultraviolet spectrophotometry (260-380 nm) using parallel factor analysis (PARAFAC) and partial least squares (PLS). The study was carried out in the pH range from 1.0 to 12.0 and with a concentration range from 0.50 to 8.75 μg ml⁻¹ of lorazepam. Multivariate calibration models using PLS at different pH and PARAFAC were elaborated for ultraviolet spectra deconvolution and lorazepam quantitation. The best models for the system were obtained with PARAFAC and PLS at pH = 2.05 (PLS-PH2). The capabilities of the method for the analysis of real samples were evaluated by determination of lorazepam in pharmaceutical preparations and biological (urine and plasma) fluids with satisfactory results. The accuracy of the method, evaluated through the root mean square error of prediction (RMSEP), was 0.0429 for lorazepam with best calibration curve by PARAFAC and 0.0467 for lorazepam with PLS model at best pH. The protolytic equilibria of lorazepam at 25 °C and ionic strength of 0.1 M have also been determined spectrophotometrically. Protolytic equilibria of lorazepam were evaluated by DATAN program using the corresponding absorption spectra-pH data. The obtained pK_a values of lorazepam are 1.54 and 11.61 for pK_a1 and pK_a2, respectively.     

Simultaneous determination of methylprednisolone and methylprednisolone 21-[8-[methyl-(2-sulfoethyl)amino]-8-oxooctanoate] sodium salt in human urine by high-performance liquid chromatography with ultraviolet detection

A reversed-phase high-performance liquid chromatographic assay with ultraviolet detection at 243 nm has been developed for the quantitative determination of methylprednisolone (MP) and methylprednisolone 21-[8-[methyl-(2-sulfoethyl)amino]-8-oxooctanoate] sodium salt (MPSO) in human urine following therapeutic doses in humans. The assay procedure involves stabilization of urine samples by addition of disodium ethylenediaminetetraacetic acid (Na2EDTA) and ion-pair extractions of MPSO using tetraethylammonium chloride (TEACl) as the counter ion. After extracting both drugs and internal standard into chloroform, the extract was evaporated to dryness under nitrogen. The resulting residue was reconstituted in 200-500 microliters of mobile phase and chromatographed on an IBM C18 reversed-phase column (5 microns). The mobile phase was a mixture of water-acetonitrile-isopropanol (71.2:18.8:10.0, v/v) containing 75 microliters of 0.1 M hydrochloric acid and 0.450 g of TEACl per liter. Propyl p-hydroxybenzoate was used as an internal standard. The extraction efficiencies of MP and MPSO were greater than 90% using the ion-pairing agent TEACl. The chromatographic responses were linear up to about 200 micrograms/ml for MP and 80 micrograms/ml for MPSO and had sufficient precision and accuracy to provide quantitative data from human urine. The assay detection limit was about 8 ng/ml for MP and 25 ng/ml for MPSO in human urine. Stability studies in urine indicated that without Na2EDTA stabilization and at room temperature, rapid degradation of MPSO occurred in urine. Addition of EDTA to the urine specimen and storage at -70 degrees C increased the stability of MPSO, and little or no degradation was observed in urine stored for more than 60 days. The method has been used in the simultaneous determination of MP and MPSO in urine specimens obtained from a single-dose tolerance study of MPSO in normal male volunteers.     

Analysis of lorazepam and its glucuronide metabolite by electron-capture gas--liquid chromatography. Use in pharmacokinetic studies of lorazepam.

This paper describes a rapid and sensitive method for analysis of lorazepam and its glucuronide metabolite in plasma and urine following therapeutic doses of lorazepam in humans. After addition of the structurally related benzodiazepine derivative, oxazepam, as the internal standard, 1-ml samples of plasma or urine are extracted twice at neutral pH with benzene (containing 1.5% isoamyl alcohol). The combined extracts are evaporated to dryness, reconstituted, and subjected to gas chromatographic analysis using a 3% OV-17 column and an electron-capture detector. Lorazepam glucuronide in urine is similarly analyzed following enzymatic cleavage with Glusulase. The sensitivity limits are 1--3 ng of analyzed following enzymatic cleavage with Glusulase. The sensitivity limits are 1--3 ng of lorazepam per ml of original sample, and the variability of identical samples is 5% or less. The applicability of the method to pharmacokinetic studies of lorazepam is demonstrated.     

Validation of SPE‐HPLC determination of 1,4‐benzodiazepines and metabolites in blood plasma,urine, and saliva

A simple, sensitive, selective, and reproducible RP‐HPLC method with DAD detection at 240 nm was developed for the determination of six 1,4‐benzodiazepines: bromazepam (BRZ), clonazepam (CLZ), diazepam (DZP), flunitrazepam (FNZ), lorazepam (LRZ), alprazolam (APZ); and two metabolites: α‐hydroxyalprazolam (HALZ) and α‐hydroxytriazolam (HTZL) in human plasma, urine, and saliva, using colchicine as internal standard, after SPE using Nexus Varian cartridges. Separation was performed on a Kromasil C₈ (250 mm×5 mm, 5 μm) analytical column with a gradient mobile phase containing methanol, ACN and 0.05 M ammonium acetate. Linearity was held within the range 0.3–20.0 ng/μL, with coefficients of determination (r²) better than 0.997. The within‐ and between‐day assay RSD at 2, 4, 8 ng/μL ranged from 0.03 to 4.7% and 0.5 to 7.0%, respectively in standards, from 1.3 to 7.9% and 3.3 to 7.3%, respectively in plasma, from 2.1 to 6.0% and 2.1 to 7.8%, respectively in urine and at 0.5, 1.0, 2.0 ng/μL ranged from 2.22 to 5.8% and 2.2 to 8.1%, respectively, in saliva. The mean relative recoveries were 96.3–108.6, 96.0–108.2, 94.3–107.1, 97.0–107.0% in within‐day assay and 96.8–107.7, 94.6–107.6, 93.2–105.8, 96.0–108.6 in between‐day assay for standard, plasma, urine, and saliva, respectively. The LOD and LOQ were 0.02–0.47 and 0.07–1.57 ng/μL, respectively.     

Determination of an aldosterone antagonist in urine by high-performance liquid chromatography using automated column switching

An automated high-performance liquid chromatographic assay for the determination of an aldosterone antagonist (I) is described using column switching for direct injection of urine samples. After dilution with buffered internal standard solution, the sample was injected onto a clean-up column (17 X 4.6 mm I.D.), dry-packed with C18 reversed-phase material (particle size 30 micron). Polar urine components were removed by flushing the clean-up column with water. Retained substances, including I and the internal standard, were desorbed by backflush elution onto a 5-micron ODS-silica analytical column (125 X 4 mm I.D.), separated with water-methanol-tetrahydrofuran, and detected at 295 nm. After backflushing the analytical column and re-equilibrating the clean-up column, the system was ready for the next injection. The limit of quantification was ca. 100 ng/ml, using a 100-microliter specimen of diluted urine. The mean inter-assay precision of the method up to 25.6 micrograms/ml was 2%. Practicability and accuracy of the new method were demonstrated by the application to excretion studies performed with human volunteers.     

Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography, comparison with microbiological methodology and stability

High-performance liquid chromatographic (HPLC) methods using ultraviolet (UV) detection have been developed for the assay of the antibiotic imipenem (N-formimidoyl thienamycin) in human plasma and urine. A reversed-phase analytical column is employed in the plasma assay method and a cation-exchange column is used in the urine assay method. Both methods use borate buffer in the mobile phase. The method of preparation of human fluid samples for HPLC injection has been optimized with respect to the stability of imipenem in aqueous buffers, in morpholine buffer--ethylene glycol stabilizer, and in urine and plasma. Preparation of the samples before injection into the HPLC systems involves deproteination/filtration of the plasma/urine samples. The open lactam metabolite and the coadministered dehydropeptidase inhibitor, cilastatin sodium, do not interfere with the 313-nm detection of imipenem in either the plasma or the urine assay. Thienamycin, the precursor of imipenem and an impurity in imipenem formulations, is separated from the drug using both of these methods. Concentrations generated from the HPLC analysis of plasma and urine samples from two healthy volunteers compare favorably with results using a microbiological assay method. Correlation of the two methods gives r greater than or equal to 0.990 for both fluids.     

Sensitive gas chromatographic--mass spectrometric screening of acetylated benzodiazepines

GC-MS screening conditions were developed for 15 low-dosed benzodiazepines, covering alprazolam, flunitrazepam, flurazepam, ketazolam, lorazepam and triazolam, and the corresponding metabolites alpha-hydroxyalprazolam, 4-hydroxyalprazolam; 7-aminoflunitrazepam, desmethylflunitrazepam, 7-aminodesmethylflunitrazepam; hydroxyethylflurazepam, N-desalkylflurazepam; oxazepam and alpha-hydroxytriazolam, respectively. Benzodiazepines are analyzed on a polydimethylsiloxane column in both the scan and the multiple ion monitoring modes using on-column injection to attain maximal sensitivity. The reactive compounds are acetylated with pyridine and acetic anhydride for 20 min. The derivatives are stable for at least 4 days. The relative standard deviation observed with standard compounds at the low nanogram-level ranged from 1.13 to 4.87% within-day and from 1.12 to 4.94% between-day. Unequivocal identification potential, high chromatographic resolution and sensitivity are combined with minimal thermal degradation. The presented screening conditions provide the basis for a unique routine screening method for low-dosed benzodiazepines with a broad polarity range.     

High-performance liquid chromatographic determination of the stereoisomeric metabolites of ibuprofen

A stereospecific reversed-phase high-performance liquid chromatographic (HPLC) method has been developed to simultaneously quantitate the stereoisomers of the two major metabolites of ibuprofen: hydroxyibuprofen and carboxyibuprofen. The metabolites were derivatized with S-(alpha)-methylbenzylamine to form diastereomeric amides which were separated and quantified on a C8 column. The validity of the stereoselective assay was confirmed by comparison with a non-stereoselective HPLC method. The stereoselective assay was applied to the quantification of all the stereoisomeric ibuprofen metabolites in urine from human volunteers dosed with racemic ibuprofen or the individual enantiomers of ibuprofen. Significant substrate and product stereo-selectivities were observed in the formation of carboxyibuprofen.     

Simultaneous Determination of β-Artemether and its Metabolite Dihydroartemisinin in Human Plasma and Urine by a High-Performance Liquid Chromatography-Mass Spectrometry Assay Using Electrospray Ionisation

A sensitive and selective method is described for the determination of β-artemether (AM) and its metabolite dihydroartemisinin (DHA) in human plasma and urine using artemisinin (IS) as internal standard. The method consists of a liquid-liquid extraction using 2,2,4-trimethylpentane – ethyl acetate (7:3 v/v) with subsequent evaporation of the supernatant to dryness followed by the analysis of the reconstituted sample by liquid chromatography – mass spectrometry (LC-MS) using positive electrospray ionisation (ESI). The acquisition was performed using a mass range scan and the ions (MH+?CH3OH) m/z 267.2, (MH+?H2O) m/z 267.2 and (MH+) m/z 283.2 for AM, DHA and IS respectively were used for compound quantifications. Chromatography was performed on a C18 reversed-phase column using a gradient of acetonitrile – ammonium acetate 10 mM, glacial acetic acid 0.1% as a mobile phase. The method was validated over a concentration range of 10–1000 ng mL^?1 using 1 mL of human plasma per assay and over a concentration range of 5–500 ng mL^?1 using 2 mL of human urine per assay. The method was applied to the quantitation of β-artemether and dihydroartemisinin in human plasma and urine of volunteers participating in a drug pharmacokinetic study.     

Simple method for the determination of inorganic sulfate in human serum and urine using single-column ion chromatography

A single-column ion chromatographic assay with conductivity detection was developed to determine inorganic sulfate concentrations in human plasma and urine samples. Plasma samples were ultrafiltered to remove proteins. Plasma ultrafiltrate and urine samples were diluted prior to injection onto the anion-exchange column. The described method is simple, fast, sensitive and reproducible and was used to study the effect of subchronic administration of acetaminophen on the plasma concentrations and urinary excretion of inorganic sulfate in healthy volunteers.